Arthroscopic Synovectomy Combined With DMARDs in the Treatment of Refractory Elbow Rheumatoid Arthritis

Peking University

Status: Unknown

Conditions: Rheumatoid Arthritis of Ankle

Treatments: Procedure: arthroscopic synovectomy

Study type: Observational

Funder types: Other

Identifiers

NCT04454034

M2019072

Details and patient eligibility

About

Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic and aggressive polyarthritis. The prevalence of RA in China is about 0.42%. Arthroscopic synovectomy (AS) is an important method to save the function of joint in the treatment of refractory RA. The clinical trial is to study the value of AS combine with DMARDs in the early stage of refractory RA.

Enrollment: 25 estimated patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• The patients who fulfilled the 1987 ACR（American College of Rheumatology) or 2010 ACR/EULAR（European League Against Rheumatism） RA classification criteria.
• The age is more than 18 years old and less than 60 years old.
• They received stable traditional DMARDs (including Chrysopidae, leflunomide, sulfasalazine, hydroxychloroquine, eilamod) or biological dmrads (including tumor necrosis factor antagonists, IL(Interleukin)-6 receptor antagonists, CD20 monoclonal antibodies) for at least 6 months.
• The disease is still in the active stage, which means the disease activity score (DAS28) is more than 3.2, and the elbow joint function is obviously limited.
• The patient agreed to undergo arthroscopic synovectomy.
• No contraindications were found.

Exclusion criteria

• The disease is in remission.
• The patient has contraindications.
• Arthroscopic synovectomy was performed in different patients.

Trial design

25 participants in 1 patient group

Group1

Description:

The refractory elbow RA who undergo arthroscopic synovectomy

Treatment:

Procedure: arthroscopic synovectomy